2019 Subependymal Giant Cell Astrocytoma Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

February 2019 | 36 pages | ID: 2290A8E124EEN
VPAResearch

Abstracts

The ongoing clinical trial research report- “2019 Subependymal Giant Cell Astrocytoma Ongoing Clinical Trials Study” analyzes the current scenario of all active Subependymal Giant Cell Astrocytoma trials across the world. The report presents top level analysis of global Subependymal Giant Cell Astrocytoma clinical trials across countries, companies and universities. It is designed to provide clear understanding into the Subependymal Giant Cell Astrocytoma trials landscape to assist users for effective long term strategy formulation to beat competition.

The report covers a key snapshot of ongoing trial count, average enrollment per trial across countries.

It also segments the Subependymal Giant Cell Astrocytoma clinical trials by-

• Region (Asia Pacific, Europe, Middle East Africa and Americas)
• Countries
• Trial Phase
• Current Trial Status (Recruiting, Active, Planned, Active but Completed Recruiting, Not Yet Recruiting etc)
• Type of the trial (Interventional, Observational)
• Sponsor Type (Companies, Universities, Government Bodies etc)
• Enrollment across types, sponsor types, geographies, current status and phases

The report also identifies the potential drug candidates under development for treatment of Subependymal Giant Cell Astrocytoma on the basis of intervention type ongoing Subependymal Giant Cell Astrocytoma trials.

The research work is prepared through extensive and continuous research on Subependymal Giant Cell Astrocytoma trials from over 150 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

REPORT SCOPE AND COVERAGE:

• All major ongoing trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Subependymal Giant Cell Astrocytoma patients are identified
• The report includes panorama of ongoing Subependymal Giant Cell Astrocytoma clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Subependymal Giant Cell Astrocytoma clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Subependymal Giant Cell Astrocytoma Ongoing Clinical Trials Overview, 2019
2.2 Premium Insights into Ongoing Clinical Trials
  2.2.1 Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials by Region
  2.2.2 Average Enrollment of Subependymal Giant Cell Astrocytoma Clinical Trials
  2.2.3 Companies participating in Ongoing Trials
  2.2.4 Drugs under Study for Subependymal Giant Cell Astrocytoma Treatment, 2019

3. REGION WISE SUBEPENDYMAL GIANT CELL ASTROCYTOMA CLINICAL TRIALS

3.1 Asia Pacific Subependymal Giant Cell Astrocytoma Clinical Trials by Country
3.2 Europe Subependymal Giant Cell Astrocytoma Clinical Trials by Country
3.3 North America Subependymal Giant Cell Astrocytoma Clinical Trials by Country
3.4 Middle East and Africa Subependymal Giant Cell Astrocytoma Clinical Trials by Country
3.5 South and Central America Subependymal Giant Cell Astrocytoma Clinical Trials by Country

4. SUBEPENDYMAL GIANT CELL ASTROCYTOMA CLINICAL TRIAL TRENDS

4.1 Start Year wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials
4.2 Phase wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials
4.3 Trial Status wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials
4.4 Trial Type wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials

5. SUBEPENDYMAL GIANT CELL ASTROCYTOMA AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Subependymal Giant Cell Astrocytoma Trials by Year
5.2 Average Enrollment in Subependymal Giant Cell Astrocytoma Trials by Phase
5.3 Average Enrollment in Subependymal Giant Cell Astrocytoma Trials by Status
5.4 Average Enrollment in Subependymal Giant Cell Astrocytoma Trials by Type of Trial

6. COMPANIES PARTICIPATING IN ONGOING SUBEPENDYMAL GIANT CELL ASTROCYTOMA CLINICAL TRIALS

6.1 Ongoing Subependymal Giant Cell Astrocytoma Trials by Sponsor Type
6.2 Subependymal Giant Cell Astrocytoma Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Ongoing Subependymal Giant Cell Astrocytoma Trials- Phase
7.2 Ongoing Subependymal Giant Cell Astrocytoma Trials- Phase
7.3 Ongoing Subependymal Giant Cell Astrocytoma Trials- Phase
7.4 Ongoing Subependymal Giant Cell Astrocytoma Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Subependymal Giant Cell Astrocytoma Ongoing Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials and Enrolment
Figure 5: Europe – Country wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials and Enrolment
Figure 7: North America – Country wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials and Enrolment
Figure 9: Subependymal Giant Cell Astrocytoma Ongoing Clinical Trials by Phase
Figure 10: Subependymal Giant Cell Astrocytoma Ongoing Clinical Trials by Trial Status
Figure 11: Subependymal Giant Cell Astrocytoma Ongoing Clinical Trials by Type
Figure 12: Subependymal Giant Cell Astrocytoma Ongoing Clinical Trials by Sponsor Type
Figure 13: Subependymal Giant Cell Astrocytoma Ongoing Clinical Trials by Leading Sponsors
Figure 14: Subependymal Giant Cell Astrocytoma Average Enrollment by Phase
Figure 15: Subependymal Giant Cell Astrocytoma Average Enrollment by Trial Status
Figure 16: Subependymal Giant Cell Astrocytoma Average Enrollment by Type
Figure 17: Subependymal Giant Cell Astrocytoma- Average Enrolment by Type of Sponsors
Figure 18: Subependymal Giant Cell Astrocytoma- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Subependymal Giant Cell Astrocytoma Ongoing Clinical Trials Snapshot- 2019
Table 2: Ongoing Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials and Enrolment
Table 5: Europe – Country wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials and Enrolment
Table 7: North America – Country wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Ongoing Subependymal Giant Cell Astrocytoma Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Subependymal Giant Cell Astrocytoma Average Enrollment by Phase
Table 15: Subependymal Giant Cell Astrocytoma Average Enrollment by Trial Status
Table 16: Subependymal Giant Cell Astrocytoma Average Enrollment by Type
Table 17: Subependymal Giant Cell Astrocytoma- Average Enrolment by Type of Sponsors
Table 18: Subependymal Giant Cell Astrocytoma- Enrolment by Leading Sponsors